



**hVIVO plc**  
**("hVIVO", the "Company" or the "Group")**

**Official launch of full suite of hLAB standalone services**

*Health & Safety Executive (HSE) clearance received for containment level 3 (CL-3) laboratory*

hVIVO plc (AIM: HVO), a fast-growing specialist contract research organisation (CRO) and world leader in testing infectious and respiratory disease products using human challenge clinical trials, announces the official launch of the full suite of its hLAB service offering, its highly specialised virology and immunology laboratory services for preclinical and clinical drug development.

hLAB is an industry leader in virology and clinical trial support and has been providing laboratory services since 1989. In recent years, due to the strong growth of the Company's human challenge trial (HCT) services, hLAB has been at capacity facilitating the delivery of these trials. Following the move to the new facility at Canary Wharf, the Company has tripled its laboratory capacity and is offering specialised virology and immunology services as standalone services. hLAB has already signed three stand-alone laboratory contracts in 2024, including its first major field study laboratory contract.

The expanded laboratory space has been specifically designed to streamline workflows and provide operational efficiencies. It includes a cutting-edge CL-3 laboratory, allowing hVIVO to work with hazard group 3 pathogens. The CL-3 lab has now received HSE clearance, and the Company has commenced operations.

hLAB has also completed a large expansion of its assay portfolio, broadening the application of its serology, PCR, infectivity assay, human peripheral blood mononuclear cells (PBMC) processing and biomarkers services for new pathogens, including Omicron, human metapneumovirus (hMPV), B. Pertussis, dengue, and additional influenza, respiratory syncytial virus (RSV) and human rhinovirus (HRV) strains. With the additional capacity at Canary Wharf, hLAB can now also expand its provision of field trial biologistics to many more clients, offering bespoke sample collection kits provision, supporting pharma companies and CROs in large multinational field studies.

In addition to these services, hLAB has also launched its biobank services and has been approved by the UK Research Ethics Committee as a Research Tissue Bank. The biobank is a comprehensive repository of a diverse range of human biological samples, providing researchers with a valuable resource to drive innovation, with a particular focus on vaccine development, immunology, and respiratory research.

Further details are available at [hlabservices.com](https://hlabservices.com)

The team from hLAB will attend the upcoming World Vaccine Congress, Europe's largest and most established meeting dedicated to vaccines, taking place at Hotel Catalonia Barcelona Plaza, Spain from 28-31 October 2024. From basic research to commercial manufacture, the event covers the whole vaccine value chain, with hundreds of speakers and thousands of attendees from leading global vaccines developers, academia and policymakers.

Attendees can meet the hLAB team at Booth Number 85. To request a meeting with hLAB at the World Vaccine Congress, interested attendees can request a meeting via the Terrapinn Event App (available from 8 October 2024) or by emailing [hlab@hvivo.com](mailto:hlab@hvivo.com).

**For further information please contact:**

**hVIVO plc** +44 (0) 20 7756 1300  
Yamin 'Mo' Khan, Chief Executive Officer  
Stephen Pinkerton, Chief Financial Officer

**Cavendish Capital Markets Limited (Nominated Adviser and Joint Broker)** +44 (0) 20 7220 0500  
Geoff Nash, Camilla Hume, Harriet Ward  
Nigel Birks - Life Science Specialist Sales

**Peel Hunt LLP (Joint Broker)** +44 (0)20 7418 8900  
James Steel, Dr Christopher Golden

**Davy (Joint Broker)** +353 (0) 1 679 6363  
Anthony Farrell, Niall Gilchrist

**Walbrook PR (Financial PR & IR)** +44 (0) 20 7933 8780 or [hvivo@walbrookpr.com](mailto:hvivo@walbrookpr.com)  
Stephanie Cuthbert, Phillip Marriage, +44 (0) 7796 794 663 / +44 (0) 7867 984 082 /  
Louis Ashe-Jepson +44 (0) 7747 515 393

**Notes to Editors**

**About hVIVO**

## hVIVO

[hVIVO plc](#) (ticker: HVO) is a fast-growing specialist contract research organisation (CRO) and the world leader in testing infectious and respiratory disease vaccines and therapeutics using human challenge clinical trials. The Group provides end-to-end early clinical development services to its large, established and growing repeat client base, which includes four of the top 10 largest global biopharma companies.

The Group's fast-growing services business includes a unique portfolio of 11 human challenge models, with a number of new models under development, to test a broad range of infectious and respiratory disease products. The Group has world class challenge agent manufacturing capabilities, specialist drug development and clinical consultancy services via its Venn Life Sciences brand, and a lab offering via its hLAB brand, which includes virology, immunology biomarker and molecular testing. The Group also offers additional clinical field trial services such as patient recruitment and clinical trial site services.

hVIVO runs challenge trials in London - its new state-of-the-art facilities in Canary Wharf opened in 2024 and is the world's largest commercial human challenge trial unit, with highly specialised on-site virology and immunology laboratories, and an outpatient unit. To recruit volunteers / patients for its studies, the Group leverages its unique clinical trial recruitment capability via its [FluCamp](#) volunteer screening facilities in London and Manchester.

This information is provided by Reach, the non-regulatory press release distribution service of RNS, part of the London Stock Exchange. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [ms@lseg.com](mailto:ms@lseg.com) or visit [www.ms.com](http://www.ms.com).

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our [Privacy Policy](#).

END

NRADZGZLKVLGDZM